{"id":4522,"date":"2025-03-31T18:12:11","date_gmt":"2025-03-31T18:12:11","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/ibandronic-acid-txt\/"},"modified":"2025-03-31T18:12:11","modified_gmt":"2025-03-31T18:12:11","slug":"ibandronic-acid-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/ibandronic-acid-txt\/","title":{"rendered":"ibandronic acid.txt"},"content":{"rendered":"

ibandronic acid <\/h1>\n

CLINICAL USE <\/H3>
\nReduction of bone damage in bone metastases in breast cancerHypercalcaemia of malignancy Post-menopausal osteoporosis

DOSE IN NORMAL RENAL FUNCTION <\/H3>Oral: 50 mg daily IV: 6 mg every 3\u20134 weeks Hypercalcaemia of malignancy: 2\u20134 mg as a single dose, repeated according to serum calcium levelPost-menopausal osteoporosis: 150 mg monthly (oral), 3 mg every 3 months (IV bolus)

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :319.2 (Ibandronate Na 359.2)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :87<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 50\u201360<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :90 litres<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :10\u201372\/Insignificantly increased1

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>30\u201350 Dose as in normal renal function. See \u2018Other Information\u201910\u201330 Oral: 50 mg weekly,

    IV infusion <\/H4>: 2 mg every 3\u20134 weeks.
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Oral: 50 mg weekly,

    IV infusion <\/H4>: 2 mg every 3\u20134 weeks.

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed.2 Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR=10\u201330 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • None known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral,

    IV infusion <\/H4>, IV bolus

    Rate of Administration <\/H4>Infusion: over 15 minutes \u2013 2 hours (depends on indication and renal function)IV bolus: over 15\u201330 seconds

    Comments<\/H4>Add dose to 100\u2013500 mL glucose 5% or sodium chloride 0.9% (depends on indication and renal function)

    OTHER INFORMATION <\/H4>Oral bioavailability <1% Swallow tablets whole with a glass of water on an empty stomach, at least 30 minutes before breakfast and any other oral medicationThe patient should stand or sit upright for at least 60 minutes after taking tabletsDon\u2019t give infusion over 15 minutes if creatinine clearance <50 mL\/min; give in 500 mL over 1 hourBolus dose is contraindicated if GFR<30 mL\/min due to lack of studiesOne study used a dose of 6 mg over 30 minutes in various degrees of renal impairment with no deterioration in renal function.1Clearance is reduced in severe renal impairmentDue to the high bone-binding effect with ibandronic acid a dose of 2 mg monthly in haemodialysis patients is equivalent to a dose of 4\u20135 mg in patients with normal renal function.3 May cause osteonecrosis of the jaw similar to other bisphosphonates
    \n","protected":false},"excerpt":{"rendered":"

    ibandronic acid CLINICAL USE Reduction of bone damage in bone<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4522","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4522"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4522\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}